Loading clinical trials...
Loading clinical trials...
An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma
Conditions
Interventions
H3B-6527
Locations
44
United States
USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States
Hoag Memorial Hospital Presbyterian
Newport Beach, California, United States
UC Irvine Medical Center
Orange, California, United States
UCLA Medical Center
Santa Monica, California, United States
Georgetown Unversity Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia, United States
Northwestern Unversity
Chicago, Illinois, United States
Start Date
December 28, 2016
Primary Completion Date
February 23, 2022
Completion Date
February 23, 2022
Last Updated
November 13, 2023
NCT07175441
NCT05969860
NCT06427941
NCT07164313
NCT07118202
NCT06503146
Lead Sponsor
H3 Biomedicine Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions